• Publications
  • Influence
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects. Expand
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
As new drugs are developed, it is suggested that the assessment processes should include both surrogate endpoints and clinical outcomes, so that patients and their physicians can be confident that the putative benefits of such drugs outweigh their risks and costs. Expand
Long-term pharmacotherapy for obesity and overweight.
Studies evaluating the long-term efficacy of anti-obesity agents are limited to orlistat and sibutramine, which appear modestly effective in promoting weight loss; however, interpretation is limited by high attrition rates. Expand
Body mass index and mortality in heart failure: a meta-analysis.
Overweight and obesity were associated with lower all-cause and cardiovascular mortality rates in patients with CHF and were not associated with increased mortality in any study. Expand
A meta-analysis of the association between adherence to drug therapy and mortality
The observed association between good adherence to placebo and mortality supports the existence of the “healthy adherer” effect, whereby adherence to drug therapy may be a surrogate marker for overall healthy behaviour. Expand
Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.
Hypertension Canada's Canadian Hypertension Education Program Guidelines Task Force provides annually updated, evidence-based recommendations to guide the diagnosis, assessment, prevention, andExpand
Statins and outcomes in patients admitted to hospital with community acquired pneumonia: population based prospective cohort study
Statins are not associated with reduced mortality or need for admission to an intensive care unit in patients with pneumonia; reports of benefit in the setting of sepsis may be a result of confounding. Expand
Hypertension Canada's 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children.
All individuals with hypertension should have an assessment of global cardiovascular risk to promote health behaviours that lower blood pressure, and an angiotensin receptor-neprilysin inhibitor combination should be used in place of either an ang Elliotensin-converting enzyme inhibitor or angiotENSin receptor blocker in individuals with heart failure. Expand
Using the Edmonton obesity staging system to predict mortality in a population-representative cohort of people with overweight and obesity
The Edmonton obesity staging system independently predicted increased mortality even after adjustment for contemporary methods of classifying adiposity, and may offer improved clinical utility in assessing obesity-related risk and prioritizing treatment. Expand
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension.
This year's update includes 2 new recommendations for the diagnosis, assessment, prevention, and treatment of hypertension in adults and discusses 2 additional topics at length (the pharmacological treatment of mild hypertension and the possibility of a diastolic J curve in hypertensive patients with coronary artery disease). Expand